Treatment of Spinal Cord Injury Patients for Neurogenic Bladder: Anticholinergic Agent vs. Mirabegron
Status:
Completed
Trial end date:
2021-03-31
Target enrollment:
Participant gender:
Summary
We propose to test the hypothesis that cognition will improve with substitution of mirabegron
for the anticholinergic agent (AC) in elderly persons with spinal cord injury (SCI) who
require neurogenic bladder (NGB) treatment.
Phase:
Early Phase 1
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio